Leone et al., 2020 - Google Patents
Metabolism of immune cells in cancerLeone et al., 2020
View PDF- Document ID
- 14487303051647926027
- Author
- Leone R
- Powell J
- Publication year
- Publication venue
- Nature reviews cancer
External Links
Snippet
Through the successes of checkpoint blockade and adoptive cellular therapy, immunotherapy has become an established treatment modality for cancer. Cellular metabolism has emerged as a critical determinant of the viability and function of both cancer …
- 201000011510 cancer 0 title abstract description 96
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leone et al. | Metabolism of immune cells in cancer | |
| Yan et al. | Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity | |
| Wu et al. | Cancer-associated adipocytes as immunomodulators in cancer | |
| Reinfeld et al. | The therapeutic implications of immunosuppressive tumor aerobic glycolysis | |
| Zhang et al. | Metabolic reprogramming and immune evasion: the interplay in the tumor microenvironment | |
| Mafi et al. | mTOR-mediated regulation of immune responses in cancer and tumor microenvironment | |
| Nobs et al. | PPARγ in dendritic cells and T cells drives pathogenic type-2 effector responses in lung inflammation | |
| Renner et al. | Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy | |
| Beckermann et al. | Dysfunctional T cell metabolism in the tumor microenvironment | |
| Le Bourgeois et al. | Targeting T cell metabolism for improvement of cancer immunotherapy | |
| Xu et al. | A metabolism toolbox for CAR T therapy | |
| Groth et al. | Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression | |
| Klein Geltink et al. | Unraveling the complex interplay between T cell metabolism and function | |
| Assmann et al. | Metabolic regulation of immune responses: therapeutic opportunities | |
| Gardiner et al. | What fuels natural killers? Metabolism and NK cell responses | |
| Vilbois et al. | Metabolic interplay: tumor macrophages and regulatory T cells | |
| Roy et al. | Immunometabolism in the tumor microenvironment | |
| Luo et al. | Fatty acid metabolism and cancer immunotherapy | |
| Simula et al. | Mitochondrial metabolism sustains CD8+ T cell migration for an efficient infiltration into solid tumors | |
| Li et al. | Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy | |
| Huang et al. | Tumor metabolic regulators: key drivers of metabolic reprogramming and the promising targets in cancer therapy | |
| Rao et al. | Metabolic profiles of regulatory T cells in the tumour microenvironment | |
| Katopodi et al. | Tumor cell metabolic reprogramming and hypoxic immunosuppression: driving carcinogenesis to metastatic colonization | |
| Degauque et al. | Regulation of the immune response by the inflammatory metabolic microenvironment in the context of allotransplantation | |
| Munford et al. | Intrinsic and extrinsic determinants of T cell metabolism in health and disease |